Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
QuintilesIMS
Julphar
Johnson and Johnson
Teva
Federal Trade Commission
US Department of Justice
US Army

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARGININE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Arginine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000623 Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed National Heart, Lung, and Blood Institute (NHLBI) N/A The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed Thalassemia Clinical Research Network N/A The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623 Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) Completed New England Research Institutes N/A The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00001436 A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma Completed National Cancer Institute (NCI) Phase 1 The suppression of IGF-I and growth hormone may significantly alter the pathobiology of osteosarcoma. SMS 201-955 pa LAR is a long acting analog of Somatostatin which inhibits the pituitary release of growth hormone, reducing levels of circulating IGF-I . Additional data on tamoxifen usage has also demonstrated a reduction in circulating IGF-I levels. The degree of suppression of IGF-I and growth hormone will be determined at two dose levels of SMS 291-955 pa LAR. Tamoxifen will be added to two of the cohorts to determine if the additive effects of tamoxifen and SMS 201-955 pa LAR will lead to additional reduction of circulating IGF-I and growth hormone levels. Arginine-stimulated GH tests to assess levels of growth hormone in the blood will be administered pre-treatment evaluation up to three times, one time on weeks 2, 8, 16, 28, 40, 52, and one month post last dose of SMS 201-955 pa LAR. The four cohorts for this study will receive 60 or 90 mg SMS 201-955 pa LAR injectable every four weeks for up to 52 weeks. Two of the cohorts will receive 10 mg Tamoxifen on a daily basis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Arginine Hydrochloride

Condition Name

Condition Name for Arginine Hydrochloride
Intervention Trials
Hypertension 10
Healthy 9
Sickle Cell Disease 7
Cardiovascular Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Arginine Hydrochloride
Intervention Trials
Diabetes Mellitus 19
Hypertension 18
Anemia, Sickle Cell 14
Diabetes Mellitus, Type 2 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Arginine Hydrochloride

Trials by Country

Trials by Country for Arginine Hydrochloride
Location Trials
United States 224
China 26
Italy 17
Canada 15
Germany 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Arginine Hydrochloride
Location Trials
California 26
Texas 21
New York 18
Maryland 15
Massachusetts 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Arginine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Arginine Hydrochloride
Clinical Trial Phase Trials
Phase 4 39
Phase 3 33
Phase 2/Phase 3 13
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Arginine Hydrochloride
Clinical Trial Phase Trials
Completed 131
Recruiting 41
Unknown status 27
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Arginine Hydrochloride

Sponsor Name

Sponsor Name for Arginine Hydrochloride
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 14
Polaris Group 10
Peking Union Medical College Hospital 8
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Arginine Hydrochloride
Sponsor Trials
Other 329
Industry 69
NIH 41
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Deloitte
Teva
Dow
Accenture
Baxter
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.